Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hang Quach

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
Internal Medicine Journal|December 26, 2023
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignanciesAshlea Campbell, Benjamin Teh, Stephen Mulligan, et al.
Future Oncology (London, England)|March 8, 2021
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study designAjay K Nooka, Katja Weisel, Niels Wcj van de Donk, et al.
Blood|July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONEJesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.
Leukemia|January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIAThierry Facon, Gordon Cook, Saad Z Usmani, et al.
Leukemia & Lymphoma|October 7, 2020
Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter studyMansi Bhurani, Lorenz Admojo, Carrie Van Der Weyden, et al.
The Lancet. Oncology|October 16, 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialThierry Facon, Shaji K Kumar, Torben Plesner, et al.
The New England Journal of Medicine|May 30, 2019
Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaThierry Facon, Shaji Kumar, Torben Plesner, et al.
Nature Medicine|August 15, 2023
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial resultsAlexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, et al.
Blood Advances|May 5, 2026
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONENizar J Bahlis, Thierry Facon, Jesús F San-Miguel, et al.
The New England Journal of Medicine|December 8, 2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A Burger, Alessandra Tedeschi, Paul M Barr, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
Internal Medicine Journal|December 26, 2023
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignanciesAshlea Campbell, Benjamin Teh, Stephen Mulligan, et al.
Future Oncology (London, England)|March 8, 2021
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study designAjay K Nooka, Katja Weisel, Niels Wcj van de Donk, et al.
Blood|July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONEJesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.
Leukemia|January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIAThierry Facon, Gordon Cook, Saad Z Usmani, et al.
Leukemia & Lymphoma|October 7, 2020
Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter studyMansi Bhurani, Lorenz Admojo, Carrie Van Der Weyden, et al.
The Lancet. Oncology|October 16, 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialThierry Facon, Shaji K Kumar, Torben Plesner, et al.
The New England Journal of Medicine|May 30, 2019
Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaThierry Facon, Shaji Kumar, Torben Plesner, et al.
Nature Medicine|August 15, 2023
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial resultsAlexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, et al.
Blood Advances|May 5, 2026
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONENizar J Bahlis, Thierry Facon, Jesús F San-Miguel, et al.
The New England Journal of Medicine|December 8, 2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A Burger, Alessandra Tedeschi, Paul M Barr, et al.
Pageof 12